ReviewPaediatric drugs2017
A Review of the Safety, Efficacy and Mechanisms of Delivery of Nasal Oxytocin in Children: Therapeutic Potential for Autism and Prader-Willi Syndrome, and Recommendations for Future Research.
Review in Paediatric drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Oxytocin in old age psychiatry: A systematic review of the safety of using intranasal oxytocin in older adults.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2025Pooled it
- Optimal dose of oxytocin to improve social impairments and repetitive behaviors in autism spectrum disorders: meta-analysis and dose-response meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2024Pooled it
- Chronic oxytocin administration as a tool for investigation and treatment: A cross-disciplinary systematic review.Neuroscience and biobehavioral reviews · 2020Pooled it
- Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability.The American journal of psychiatry · 2024Trial
- Safety and tolerability of chronic intranasal oxytocin in older men: results from a randomized controlled trial.Psychopharmacology · 2021Trial
- The effect of intranasal oxytocin on visual processing and salience of human faces.Translational psychiatry · 2020Trial
- A new approach of ocular nebulization with vitamin B12 versus oxytocin for the treatment of dry eye disease: an in vivo confocal microscopy study.Drug design, development and therapy · 2019Trial
- No side-effects of single intranasal oxytocin administration in middle childhood.Psychopharmacology · 2018Trial
- Development and characterisation of novel oxytocin analogues for PET imaging.Communications chemistry · 2025Article
- Mediating Impact of Intranasal Oxytocin on the Interaction Between Irritability and Reactive Aggression in Youth with Severe Irritability.Life (Basel, Switzerland) · 2025Article
- The impact of the early environment on oxytocin receptor epigenetics and potential therapeutic implications.Pediatric research · 2025Review
- Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome.Pharmacology & therapeutics · 2024Review
- Emphasizing autonomic dysregulation evaluation contributes to the diagnosis of ROHHAD syndrome.Endocrine connections · 2024Article
- Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Intranasal drug delivery: opportunities and toxicologic challenges during drug development.Drug delivery and translational research · 2022Review
- Effects of intranasal oxytocin on neural reward processing in children and adolescents with reactive attachment disorder: A randomized controlled trial.Frontiers in child and adolescent psychiatry · 2022Article
- The Importance of Experimental Investigation of the CNS Oxytocin System.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Serum Oxytocin Level Correlates With Gut Microbiome Dysbiosis in Children With Autism Spectrum Disorder.Frontiers in neuroscience · 2021Article
- Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research.Molecular psychiatry · 2021Review
- Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study.Translational psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
In this article, we conduct a comprehensive review of existing evidence for the safety and therapeutic potential of intranasal oxytocin in pediatric populations. Unique considerations for dosing and delivery of oxytocin to the nasal passageway in pediatric populations and methods to promote adherence are reviewed. Intranasal oxytocin has been administered to 261 children in three open-label studies and eight randomized controlled trials. To date, the only published results in pediatric populations have focused on autism spectrum disorder (ASD) and Prader-Willi syndrome (PWS). Results regarding efficacy for improving social impairment in ASD are equivocal, partially due to mixed methodological designs, dosing regimens, and outcome measures. At present, there is no randomized controlled evidence that oxytocin provides benefit to individuals with PWS. There is no clear evidence of a link between oxytocin administration and any specific adverse event. Adverse events have been assessed using medical interviews, open reports, checklists, and physiological assessments. Adverse events reports have been largely classified as mild (n = 93), with few moderate (n = 9) or severe (n = 3) events reported. There were 35 additional adverse events reported, without severity ratings. Severe events, hyperactivity and irritability, occurred at first administration in both placebo and oxytocin groups, and subsided subsequent to discontinuation. We note that adverse event monitoring is inconsistent and often lacking, and reporting of its relationship to the study drug is poor. Only one study reported adherence data to suggest high adherence. Recommendations are then provided for the delivery of nasal sprays to the nasal passageway, monitoring, and reporting of efficacy, safety, and adherence for oxytocin nasal spray trials in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.